Form 4: PHIO CEO Granted 120,000 Restricted Stock Units

Phio Pharmaceuticals Corp. CEO Robert J. Bitterman was granted 120,000 restricted stock units, vesting on the first anniversary of the grant date.

Summary

• Robert J. Bitterman, Chairman, President, and CEO of Phio Pharmaceuticals Corp., was granted 120,000 shares of common stock.
• These shares represent restricted stock units (RSUs) with a transaction price of $0.
• The RSUs are scheduled to vest on the first annual anniversary of the grant date, which is February 5, 2027.
• Following this transaction, Mr. Bitterman's total beneficial ownership, including unvested restricted stock units, is 411,421 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns management incentives with shareholder interests, a standard practice in executive compensation.

Positives

• The grant of restricted stock units aligns management's interests with long-term shareholder value.
• Equity compensation at a $0 price is a common incentive for executives.

Negatives

• The shares are restricted and do not vest until February 5, 2027, meaning no immediate liquidity for the executive.
• The grant could lead to future dilution upon vesting, though this is typical for equity compensation plans.

Future Outlook

The 120,000 restricted stock units granted to the CEO are scheduled to vest on February 5, 2027, contingent on continued service.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through restricted stock units, is a standard practice in the biotechnology and pharmaceutical industries to incentivize executive performance and align their interests with long-term shareholder value. This grant is consistent with typical executive compensation structures aimed at retention and performance.

Comparison to Industry Standards

• The grant of restricted stock units to a CEO is a common form of executive compensation across various industries, including biotech.
• Companies like Moderna (MRNA) and Pfizer (PFE) frequently use RSU grants as part of their executive compensation packages to retain talent and link pay to performance.
• The vesting schedule of one year is relatively short compared to some multi-year vesting schedules, but still provides a future incentive.

Related Party Transactions

• The grant of restricted stock units to the CEO is a related party transaction, as it involves compensation to an executive.

Stakeholder Impact

• Shareholders: Potential long-term benefit from increased management alignment; minor potential future dilution upon vesting.
• Employees: No direct impact mentioned, but could signal stability in executive leadership.
• Management: Increased equity stake and long-term incentive.

Next Steps

• The 120,000 restricted stock units are expected to vest on February 5, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine equity compensation grant to the CEO, which is a standard practice for aligning executive incentives. It does not contain information that would fundamentally alter the investment thesis for Phio Pharmaceuticals Corp. Therefore, a "hold" recommendation is appropriate, as this event alone is unlikely to drive significant price movement but reinforces existing compensation strategies.

Keywords

Phio Pharmaceuticals, PHIO, Robert J. Bitterman, Restricted Stock Units, RSU, Equity Compensation, Insider Transaction, Form 4, CEO Grant, Executive Compensation